Senaparib
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Senaparib
- Molecular weight
- 478.46
- Structure (SMILES)
- O=C(c1cc(Cn2c(=O)[nH]c(=O)c3c(F)cccc32)ccc1F)N1CCN(c2ncccn2)CC1
- imp 4297
- IMP-4297
- imp4297
- Imp4297
- IMP4297
- IMP4297 100 mg
- IMP4297 40 mg
- IMP4297(10mg)
- IMP4297(20mg)
- IMP4297(senaparib)
- senaparib
- Senaparib
- senaparib [INN]
- Senaparib [WHO-DD]
- Senaparib capsules(10mg)
- Senaparib capsules(20mg)
- senaparib inn
- senaparib who dd
- CAS registry numbers
- 1401682-78-7
- ChEMBL ID
- CHEMBL4802152
- InChIKey
- VBTUJTGLLREMNW-UHFFFAOYSA-N
- PubChem compound IDs
- 68389008
- FDA ingredient codes (UNII)
- MNZ4OP95CF
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- senaparib
- Type
- Synthetic organic
- Drug name stem
- -parib
- Approval recorded by Guide to Pharmacology
- Yes
- Mechanism
- Poly [ADP-ribose] polymerase 2 inhibitor
- Action type
- Inhibitor
- Target
- Poly [ADP-ribose] polymerase 2
- Protein identifier
- Q9UGN5
- Mechanism
- Poly [ADP-ribose] polymerase-1 inhibitor
- Action type
- Inhibitor
- Target
- Poly [ADP-ribose] polymerase 1
- Protein identifier
- P09874
- Mechanism
- Poly [ADP-ribose] polymerase 2 inhibitor
- Action type
- Inhibitor
- Target
- Poly [ADP-ribose] polymerase 2
- Mechanism
- Poly [ADP-ribose] polymerase-1 inhibitor
- Action type
- Inhibitor
- Target
- Poly [ADP-ribose] polymerase 1
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0004992
- Subject identifier
- D009369
- Condition
- Breast Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0007254
- Subject identifier
- D001943
- Condition
- Ovarian Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0008170
- Subject identifier
- D010051
- Condition
- Prostatic Neoplasms, Castration-Resistant
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0008315
- Subject identifier
- D064129
- Condition identifier
- EFO_0000616
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0000548
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002158
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0004992
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0006335
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0007254
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0008170
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0008170
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0008315
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0008433
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0015686
- Highest recorded phase
- 3
- NCT03507543
- NCT04089189
- NCT04057729
- NCT04351165
- NCT04584515
- NCT05109832
- NCT05390944
- NCT05391048
- NCT05262842
- Hydrogen bond acceptors
- 7
- Hydrogen bond donors
- 1
- Polar surface area
- 104.19
- Calculated partition coefficient (ALogP)
- 1.77
- Calculated partition coefficient (XLogP)
- 2
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 4
- Heavy atoms
- 35
- Molecular formula
- C24H20F2N6O3
- Monoisotopic mass
- 478.15649485
- Natural product
- No
Related records
Trials (17)
- A Bioequivalence Study to Compare Senaparib Manufactured at 2 Sites in Healthy Subjects in Fasting State
- A Prospective Observational Study of Senaparib in the Treatment of Epithelial Ovarian Cancer
- A Study of Absorption-Distribution-Metabolism-Excretion (ADME) of [14C]IMP4297 to China Healthy Male Subjects
- A Study of IMP4297 in Patients With Advanced Solid Tumors
- An BE Study to Compare 10mg & 20mg of IMP4297 Capsules in Healthy Chinese Subjects Under Fasting Condition
- An BE Study to Compare 10mg & 20mg of IMP4297 Capsules in Healthy Chinese Subjects Under Fed Condition
- An Bioequivalence Study to Compare 10mg & 20mg of Senaparib Capsules in Healthy Chinese Subjects Under Fasting Condition
- BA Study of IMP4297 (20mg vs 10mg) in Healthy Male Subjects
- Combination Therapy of Senaparib and Bevacizumab for First-line Maintenance Therapy in Newly Diagnosed Advanced Homologous Recombination Proficient Ovarian Cancer Based on Exosome Protein Marker
- IMP4297 DDI (Drug-Drug Interaction)Trial in Healthy Male Volunteers
- IMP4297 Food Effect Trial in Healthy Volunteers
- IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer
- JS001+IMP4297 in Patients With Advanced Cancer
- Senaparib in mCRPC Patients With Homologous Recombination Repair Gene Alterations After Docetaxel Treatment
- Study of IMP4297 in Patients With BRCA1/2 Mutation Ovarian Cancer
- Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer
- The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors
In development for (5)
- Breast cancer Phase 1
- Cancer Phase 1
- Neoplasm Phase 1
- Ovarian cancer Phase 2
- Prostate cancer Phase 1